Compare CWCO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWCO | PRTA |
|---|---|---|
| Founded | 1973 | 2012 |
| Country | Cayman Islands | Ireland |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.1M | 539.9M |
| IPO Year | 1997 | 2013 |
| Metric | CWCO | PRTA |
|---|---|---|
| Price | $30.03 | $9.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $40.00 | $19.00 |
| AVG Volume (30 Days) | 103.6K | ★ 393.6K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.23 | ★ 0.60 |
| Revenue | ★ $132,073,368.00 | $814,000.00 |
| Revenue This Year | $4.34 | $1,111.38 |
| Revenue Next Year | $42.86 | N/A |
| P/E Ratio | $130.48 | ★ $16.05 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.16 | $4.32 |
| 52 Week High | $39.12 | $11.80 |
| Indicator | CWCO | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 29.48 | 40.83 |
| Support Level | N/A | $8.26 |
| Resistance Level | $34.43 | $9.90 |
| Average True Range (ATR) | 0.89 | 0.61 |
| MACD | -0.24 | -0.21 |
| Stochastic Oscillator | 8.66 | 14.68 |
Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties. The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal, and industrial water production, supply, and treatment, and the corporate segment.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.